Abstract: In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.
Type:
Grant
Filed:
March 30, 2005
Date of Patent:
October 31, 2006
Assignee:
Euro-Celtique, S.A.
Inventors:
Robert Chapman, Lonn S. Rider, Qi Hong, Donald Kyle, Robert Kupper
Abstract: Dosage regimens of buprenorphine to treat withdrawal or abstinence syndrome in a drug dependent or opioid tolerant patient who is pregnant are described. The method includes treating withdrawal or abstinence syndrome of the patient by transdermal administration of an amount of buprenorphine effective to reduce withdrawal symptoms. For example, a first buprenorphine-containing transdermal dosage form for a second dosing period that is no more than about 5 days, the second dosage form comprising the same or a greater dosage of buprenorphine than the first dosage form; and a third buprenorphine-containing transdermal dosage form for a third dosing period that is at least 2 days, the third dosage form comprising the same or a greater dosage of buprenorphine than the second dosage form.
Abstract: The present invention provides compound having the structure: and pharmaceutically acceptable salts or derivatives thereof, as well as compositions including such compounds. The invention also provides methods of (1) preventing pain, (2) treating pain, (3) inducing sedation, (4) treating opiate addiction, (5) treating opiate withdrawal (abstinence syndrome) and/or (6) treating cough in a patient in need thereof by administering a compound or composition of the invention.
Type:
Grant
Filed:
March 4, 2002
Date of Patent:
October 24, 2006
Assignee:
Euro-Celtique S.A.
Inventors:
Bruce E. Reidenberg, Donna-Donigi Gale, Vinayak J. Srinivasan
Abstract: The present invention provides provide a dosage form that prevents misuse of the medicament contained within. The dosage form contains an inactivating substance in combination with the medicament, wherein the two substances are separated by a permeable or semi-permeable partition. The partition becomes impermeable upon activation by a medical professional, thereby effectively sequestering the inactivating substance from the medicament and allowing for the intended administration of the medicament to the patient. Unless activated, however, the inactivating substance and medicament remain commingled in the dosage form, and any attempt to dispense the medicament before activation will result in the release of inactivated medicament.
Abstract: This invention relates aryl substituted pyridines of Formula I: or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein Ar and R1–R4 are set in the specification. The invention is also directed to the use of compounds of Formula I for the treatment of neuronal damage following global and focal ischemia, for the treatment or prevention of neurodegenerative conditions such as amyotrophic lateral sclerosis (ALS), and for the treatment, prevention or amelioration of both acute or chronic pain, as antitinnitus agents, as anticonvulsants, and as antimanic depressants, as local anesthetics, as antiarrhythmics and for the treatment or prevention of diabetic neuropathy.
Type:
Grant
Filed:
September 6, 2002
Date of Patent:
September 12, 2006
Assignee:
Euro-Celtique S.A.
Inventors:
Bin Shao, R. Richard Goehring, Samuel F Victory, Qun Sun
Abstract: Disclosed is a pharmaceutical composition comprising from about 5 to about 20 mg of hydrocodone or a pharmaceutically acceptable salt thereof and from 0.055 to about 0.56 mg naltrexone or pharmaceutically acceptable salt thereof.
Type:
Application
Filed:
September 9, 2004
Publication date:
August 31, 2006
Applicant:
EURO-CELTIQUE S.A.
Inventors:
Benjamin Oshlack, Curtis Wright, Chris Breder
Abstract: In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.
Type:
Application
Filed:
March 29, 2006
Publication date:
August 3, 2006
Applicant:
Euro-Celtique S.A.
Inventors:
Robert Chapman, Lonn Rider, Qi Hong, Donald Kyle, Robert Kupper
Abstract: The invention is directed to oral modified/controlled release methylphenidate formulations which provide a rapid initial onset of effect and a prolonged duration of effect. Preferably, the peak concentration is lower than that provided by the reference standard for immediate release methylphenidate formulations, and the duration of effect falls rapidly at the end of the dosing interval so as not to affect the appetite of the patient at dinner nor the patient's sleep thereafter.
Type:
Grant
Filed:
December 19, 2003
Date of Patent:
August 1, 2006
Assignee:
Euro-Celtique S.A.
Inventors:
Paul D. Goldenheim, Richard S. Sackler, Thinnayam N. Krishnamurthy, Andrew Darke, Benjamin Oshlaci
Abstract: This invention relates to compounds having the Formula I: or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein Het and R5-R8 are set in the specification. The invention also is directed to the use of compounds of Formula I for the treatment of neuronal damage following global and focal ischemia, for the treatment or prevention of neurodegenerative conditions such as amyotrophic lateral sclerosis (ALS), and for the treatment, prevention or amelioration of both acute or chronic pain, as antitinnitus agents, as anticonvulsants, and as antimanic depressants, as local anesthetics, as antiarrhythmics and for the treatment or prevention of diabetic neuropathy.
Type:
Grant
Filed:
March 22, 2001
Date of Patent:
July 18, 2006
Assignee:
Euro-Celtique S.A.
Inventors:
Derk J. Hogenkamp, Phong Nguyen, Ji Yang
Abstract: A blending apparatus comprises a blender including a container having a wall, the wall including a window. The container rotates about an axis of rotation. A wireless spectrometer is mounted to the container and operates through the window, in a direction that does not intersect the axis of rotation, for obtaining a set of spectroscopic data regarding the product during an operation of the blender. In addition, a method for assaying a blended product in a blender includes mounting a wireless spectrometer to the container, rotating the container about its axis of rotation so as to blend the product; operating the wireless spectrometer through a window in the container, in a direction that does not intersect the axis of rotation, to obtain spectroscopic data regarding the product during the blending, and determining a homogeneity of the product from the spectroscopic data.
Type:
Grant
Filed:
April 30, 2003
Date of Patent:
July 11, 2006
Assignee:
Euro-Celtique S.A.
Inventors:
Lane Gehrlein, Emil Ciurczak, Gary Ritchie
Abstract: A controlled release preparation for oral administration contains tramadol, or a pharmaceutically acceptable salt thereof, as active ingredient.
Type:
Grant
Filed:
March 6, 2001
Date of Patent:
July 11, 2006
Assignee:
Euro-Celtique S.A.
Inventors:
Ronald Brown Miller, Sandra Therese Antoinette Malkowska, Walter Wimmer, Udo Hahn, Stewart Thomas Leslie, Kevin John Smith, Horst Winkler, Derek Allan Prater
Abstract: A Compound of formula (wherein X is O or S and R1–R5 are disclosed herein) or a pharmaceutically acceptable salt thereof (each being a “Piperazine Compound”), pharmaceutical compositions comprising a Piperazine Compound and methods for treating or preventing pain, UI, an ulcer, IBD, IBS, an addictive disorder, Parkinson's disease, parkinsonism, anxiety, epilepsy, stroke, a seizure, a pruritic condition, psychosis, a cognitive disorder, a memory deficit, restricted brain function, Huntington's chorea, amyotrophic lateral sclerosis, dementia, retinopathy, a muscle spasm, a migraine, vomiting, dyskinesia, or depression in an animal comprising administering to an animal in need thereof an effective amount of a Piperazine Compound are disclosed.
Abstract: An apparatus for detecting the homogeneity of a pharmaceutical mixture has a hopper for containing a mixture of two or more pharmaceutical components and that is situated within a production line of preparation of a pharmaceutical dosage form. A spectroscope is mounted to the hopper for measuring spectroscopic characteristics of the mixture, and a processing device that is not physically coupled to the spectroscope analyzes the spectroscopic characteristics of the mixture and derives information regarding the homogeneity of the mixture. The spectroscope wirelessly sends the spectroscopic characteristics to the processing device, which derives information regarding the homogeneity of the mixture. The wireless transmission of the spectroscopic characteristics can be done through infrared radiation or near infrared radiation, and the spectroscopic characteristics can be converted to digital signals prior to being transmitted.
Type:
Grant
Filed:
April 3, 2003
Date of Patent:
June 6, 2006
Assignee:
Euro-Celtique S.A.
Inventors:
Lane Gehrlein, Emil Ciurczak, Gary Ritchie, Kevin C. Bynum
Abstract: Disclosed are compounds of the formula (I) wherein R1, R2, R3 R4 R5, R6 and N are as disclosed herein. The compounds are useful for the treatment of chronic and acute pain.
Abstract: The present invention provides immunoglobulins specific for p53BP2 ligand polypeptides. In a preferred embodiment, the present invention provides a variant of an immunoglobulin variable domain, wherein the immunoglobulin variable domain contains (A) at least one CDR region and (B) framework regions flanking the CDR, and the variant includes: (a) the CDR region having added or substituted therein at least one binding sequence, and (b) the flaking framework regions, wherein the binding sequence is heterologous to the CDR and the binding sequence is derived from a human ligand having immunogenic properties relevant to human lung cancer. In a preferred embodiment, the binding sequence is an antigenic sequence. In a further preferred embodiment, the variant contains a variable domain lacking an intrachain disulfide bond.
Abstract: This invention relates aryl substituted benzimidazoles of Formula I: or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein R1, R2, R10 and n are defined in the specification. The invention is also directed to the use of compounds of Formula I for the treatment of neuronal damage following global and focal ischemia, for the treatment or prevention of neurodegenerative conditions such as amyotrophic lateral sclerosis (ALS), and for the treatment, prevention or amelioration of both acute or chronic pain, as antitinnitus agents, as anticonvulsants, and as antimanic depressants, as local anesthetics, as antiarrhythmics and for the treatment or prevention of diabetic neuropathy.
Abstract: A method of effectively treating hypertension in humans is achieved by administering felodipine via a transdermal formulation. Preferably, the transdermal formulation is applied to the skin of the patient and maintained in contact with the skin for at least about 24 hours days, and preferably for about 3 to about 8 days.
Abstract: Triazaspiro Compounds, compositions comprising a Triazaspiro Compound, methods for treating or preventing pain in an animal comprising administering to an animal in need thereof an effective amount of a Triazaspiro Compound and methods for stimulating opioid-receptor function in a cell comprising contacting a cell capable of expressing an opioid receptor with an effective amount of a Triazaspiro Compound are disclosed.
Abstract: Disclosed are compounds of the formula (I) wherein R1, R2 R3 R4 R5, R6 and N are as disclosed herein. The compounds are useful for the treatment of chronic and acute pain.
Type:
Grant
Filed:
December 6, 2000
Date of Patent:
January 10, 2006
Assignee:
Euro-Celtique, S.A.
Inventors:
Donald Kyle, R Richard Goehring, Sam Victory